Form 8-K · Current Report · Filed 2024-08-21
Agilent Technologies Reports Third-Quarter 2024 Results and Updates Guidance
Agilent Technologies, Inc. reported a 5.6% decline in third-quarter revenue to $1.58 billion and a 155% increase in GAAP net income to $282 million. Non-GAAP net income was $385 million, down 8% from the prior year. The company raised its full-year revenue outlook to $6.450 billion to $6.500 billion and adjusted its non-GAAP earnings guidance to a range of $5.21 to $5.25 per share. The fourth-quarter revenue outlook is expected to be between $1.641 billion and $1.691 billion, with non-GAAP EPS guidance of $1.38 to $1.42.
- Filer
- Agilent Technologies Inc. A · NYSE
- Filed
- Accession
- 0001090872-24-000024
- CIK
- 0001090872
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$139.75
Next session
+0.3%
Since filing
-1.0%
Latest close
$138.37
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from A reporting the same item, with the next session's move:
Exhibits (1)
About Agilent Technologies Inc.
Agilent Technologies Inc. is a global leader in the development and provision of life sciences, diagnostics, and applied chemical markets. Primarily focused on delivering superior analytical instruments, software, services, consumables, and reagents, the company plays a critical role in supporting the research needs of pharmaceutical, biotechnology, and government laboratories. Agilent's robust portfolio includes innovative solutions for genomics, proteomics, and metabolomics, aiding in critical areas such as disease research, food safety, and environmental analysis. Established in 1999 as a spin-off from Hewlett-Packard, the company leverages its heritage of technological innovation to enhance analytical capabilities for its clients. Agilent's significant contributions to health and safety applications underscore its importance in advancing scientific understanding and supporting public health initiatives worldwide.
Never miss another A filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.